

Protocol

# Integration of Digital Phenotyping and Genomics for Dry Eye Disease: Protocol for a Prospective Cohort Study

Ken Nagino<sup>1,2,3,4\*</sup>, PhD; Yasutsugu Akasaki<sup>1,2\*</sup>, MD, PhD; Nobuo Fuse<sup>5,6</sup>, MD, PhD; Soichi Ogishima<sup>5,6</sup>, PhD; Atsushi Shimizu<sup>7,8</sup>, PhD; Akira Uruno<sup>5</sup>, MD, PhD; Yoichi Sutoh<sup>7,9</sup>, PhD; Yayoi Otsuka-Yamasaki<sup>7,9</sup>, PhD; Fuji Nagami<sup>5,6</sup>, PhD; Jun Seita<sup>8</sup>, MD, PhD; Tomohiro Nakamura<sup>5,10</sup>, PhD; Satoshi Nagaie<sup>5</sup>, PhD; Makiko Taira<sup>5,11,12</sup>, MD, PhD; Tomoko Kobayashi<sup>5</sup>, MD, PhD; Ritsuko Shimizu<sup>5,6</sup>, MD, PhD; Atsushi Hozawa<sup>5</sup>, MD, PhD; Shinichi Kuriyama<sup>5,6</sup>, MD, PhD; Atsuko Eguchi<sup>3</sup>, PhD; Akie Midorikawa-Inomata<sup>3,4</sup>, MPH, PhD; Masahiro Nakamura<sup>1</sup>, MD, PhD; Akira Murakami<sup>1</sup>, MD, PhD; Shintaro Nakao<sup>1</sup>, MD, PhD; Takenori Inomata<sup>1,2,3,4,13</sup>, MD, MBA, PhD

<sup>1</sup>Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan

<sup>2</sup>Department of Digital Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

<sup>3</sup>Department of Hospital Administration, Juntendo University Graduate School of Medicine, Tokyo, Japan

<sup>4</sup>Department of Telemedicine and Mobile health, Juntendo University Graduate School of Medicine, Tokyo, Japan

<sup>5</sup>Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan

<sup>6</sup>Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Japan

<sup>7</sup>Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate Medical University, Yahaba, Japan

<sup>8</sup>Advanced Data Science Project, RIKEN Information R&D and Strategy Headquarters, RIKEN, Tokyo, Japan

<sup>9</sup>Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Iwate Medical University, Yahaba, Japan

<sup>10</sup>Department of Data Science, Kyoto Women's University, Kyoto, Japan

<sup>11</sup>Department of Neurology, Neuroscience & Sensory Organs, Tohoku University Graduate of Medicine, Sendai, Japan

<sup>12</sup>Department of Neurology, Tohoku University Hospital, Sendai, Japan

<sup>13</sup>Data Science, Juntendo University Graduate School of Medicine, Tokyo, Japan

\*these authors contributed equally

## Corresponding Author:

Takenori Inomata, MD, MBA, PhD

Department of Ophthalmology

Juntendo University Graduate School of Medicine

2-1-1 Hongo

Bunkyo-ku

Tokyo, 1130033

Japan

Phone: 81 338133111

Email: [tinoma@juntendo.ac.jp](mailto:tinoma@juntendo.ac.jp)

## Abstract

**Background:** Dry eye disease (DED) is a common ocular condition with diverse and heterogeneous symptoms. Current treatment standards of DED include the post facto management of associated symptoms through topical eye drops. However, there is a need for predictive, preventive, personalized, and participatory medicine. The DryEyeRhythm mobile health app enables real-time data collection on environmental, lifestyle, host, and digital factors in a patient's daily environment. Combining these data with genetic information from biobanks could enhance our understanding of individual variations and facilitate the development of personalized treatment strategies for DED.

**Objective:** This study aims to integrate digital data from the DryEyeRhythm smartphone app with the Tohoku Medical Megabank database to create a comprehensive database that elucidates the interplay between multifactorial factors and the onset and progression of DED.

**Methods:** This prospective observational cohort study will include 1200 participants for the discovery stage and 1000 participants for the replication stage, all of whom have data available in the Tohoku Medical Megabank database. Participants will be recruited

from the Community Support Center of Sendai, Miyagi Prefecture, Japan. Participant enrollment for the discovery stage was conducted from August 1, 2021, to June 30, 2022, and the replication stage will be conducted from August 31, 2024, to March 31, 2026. Participants will provide demographic data, medical history, lifestyle information, DED symptoms, and maximum blink interval measurements at baseline and after 30 days using the DryEyeRhythm smartphone app. Upon scanning a registration code, each participant's cohort ID from the Tohoku Medical Megabank database will be linked to their smartphone app, enabling data integration between the Tohoku Medical Megabank and DryEyeRhythm database. The primary outcome will assess the association between genetic polymorphisms and DED using a genome-wide association study. Secondary outcomes will explore associations between DED and various factors, including sociodemographic characteristics, lifestyle habits, medical history, biospecimen analyses (eg, blood and urine), and physiological measurements (eg, height, weight, and eye examination results). Associations will be evaluated using logistic regression analysis, adjusting for potential confounding factors.

**Results:** The discovery stage of participant enrollment was conducted from August 1, 2021, to June 30, 2022. The replication stage will take place from August 31, 2024, to March 31, 2026. Data analysis is expected to be completed by September 2026, with results reported by March 2027.

**Conclusions:** This study highlights the potential of smartphone apps in advancing biobank research and deepening the understanding of multifactorial DED, paving the way for personalized treatment strategies in the future.

**International Registered Report Identifier (IRRID):** DERR1-10.2196/67862

(*JMIR Res Protoc* 2025;14:e67862) doi: [10.2196/67862](https://doi.org/10.2196/67862)

## KEYWORDS

dry eye syndrome; dry eye disease; mobile health; smartphone; biobank; ocular surface; digital health; genome-wide association study

## Introduction

Dry eye disease (DED) is one of the most diagnosed ocular conditions, with an estimated prevalence of 5%-50% [1]. It is associated with several recent global trends, including an aging population, a digitalized society, and cultural changes related to the COVID-19 pandemic [2-4]. The economic burden caused by the negative impact of DED on quality of life and vision is estimated at US \$3.84 billion in the United States [5]. Patients with DED present with a highly heterogeneous range of symptoms, including dryness, photophobia, eye fatigue, and decreased visual acuity [6-8]. This situation presents a diagnostic challenge for clinicians, as several DED symptoms are nonspecific, resulting in a substantial number of patients being undiagnosed and untreated [9].

The progression of DED to severe stages, as observed in cases of Sjögren syndrome, graft-versus-host disease, and Stevens-Johnson syndrome, can lead to the development of corneal epithelial disorders that are refractory to existing therapies. Consequently, patients may experience severe pain, infectious keratitis, corneal perforations, and vision loss due to corneal neovascularization [10]. Current standards for DED treatment involve the post-facto management of associated symptoms using topical eye drops. However, no definitive cure exists for this chronic condition, which often affects individuals throughout their lives. Therefore, clinicians should actively implement preventive and predictive medicine strategies to prevent the onset and progression of DED. These strategies involve identifying risk factors and exploring new biomarkers to assist providers in anticipating disease progression [6-8].

From a pathophysiological perspective, DED is considered a multifactorial disease that disrupts tear film layer homeostasis [11]. Its onset and progression arise from the interplay of various factors, which are broadly divided into 3 categories: lifestyle

factors (diet, cigarette use, physical activity, on-screen time, and contact lens use), environmental factors (humidity, pollen level, and particulate matter 2.5), and host factors (age, sex, presence of collagen diseases, family medical history, and genetic predispositions) [1]. Therefore, improving the current understanding and treatment of DED requires a comprehensive assessment of each patient's health status. Several clinicians recommend effective strategies for preventive, predictive, personalized, and participatory medicine (P4 medicine). These strategies include a holistic review of associated factors using personalized digital data on lifestyle patterns and digital phenotypes obtained through mobile health (mHealth) apps and integrating mHealth data with comprehensive biomedical data, such as genomic composition and DED-related laboratory findings [1,12].

mHealth, as defined by the World Health Organization, refers to a broad range of "medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices" [13]. Recent advancements in portable smart devices have accelerated global efforts to implement mHealth in clinical practice [14]. Compared with existing electronic medical record software or epidemiologic studies, mHealth-based studies facilitate the collection of personal longitudinal health data, such as daily symptoms and lifestyle factors, with minimal intrusion. They also provide access to different types of comprehensive digital data, including those from embedded biosensors and real-time environmental information available online [6-9,15]. mHealth enables the collection of longitudinal, high-frequency, real-time, and remote data for clinicians and researchers. In addition, it supports bidirectional participatory medicine, allowing users and participants to provide active feedback [16]. Informed consent for research participation can be obtained digitally, reducing

access barriers and increasing outreach to traditionally secluded populations [17].

To facilitate the implementation of P4 medicine, we launched DryEyeRhythm, an in-house mHealth app for DED research, in 2016 and 2020 for iOS and Android, respectively. To date, DryEyeRhythm has enrolled over 55,000 participants who have provided comprehensive real-world data, including subjective symptoms, digital information, lifestyle factors, environmental status, and biosensor data [7,9,15,17-20]. For our digital cohort studies on DED variability and heterogeneity, the DryEyeRhythm app has been pivotal in monitoring digital data, lifestyle factors, environmental data, and symptom changes that reflect participants' daily life and activity patterns.

A study based on the TwinsUK registry cohort [21] indicated that several chronic pain syndromes, including DED, demonstrated genetic heritability. A follow-up metabolome study revealed several metabolites associated with DED. Multiple gene loci are hypothesized to influence the onset and progression of DED, with several gene polymorphisms playing a crucial role in DED pathogenesis [22-39]. Polymorphisms in the estrogen receptor  $\alpha$  and vitamin D receptor gene *APA-1* (rs7975232) have been associated with an increased prevalence of DED in several ethnic groups [22-24,28]. However, as of December 2023, no comprehensive reports on the genetic factors underlying DED heritability from genome-wide association studies (GWAS) have been published. Although numerous genetic factors contribute to DED heritability, the lack of GWAS limits the understanding of gene loci associated with DED onset and progression, hindering the provision of personalized medicine.

The Tohoku Medical Megabank (TMM) project was established in 2012 to support the reconstruction of areas affected by the Great East Japan Earthquake, promote the health of affected populations, and provide personalized and preventive medicine [40]. Collaborating with the Tohoku University and Iwate TMM Organizations in Miyagi and Iwate Prefectures, respectively, a 3-generation cohort study involving 150,000 local participants was conducted. The collected medical samples and data have established a foundation for a large-scale biobank [40-42].

This study conducts an add-on study to integrate DED-related personalized digital data, such as lifestyle factors and activity patterns, with the existing TMM databases by providing the DryEyeRhythm app to the participants of TMM cohort studies. These TMM databases include genomics, epidemiologic data, medical history, medical sample analyses, and physiological function testing results. Ultimately, we seek to establish a novel,

comprehensive database for DED to elucidate the interplay between environmental factors, lifestyle choices, host factors, gene loci, and polymorphism traits that contribute to the onset and progression of DED, as well as to identify new DED subtypes through stratification techniques.

## Methods


### The TMM Project

As part of the TMM project, an integrated biobank was established based on the TMM Community-Based Cohort Study (TMM CommCohort Study) and TMM Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study). The study design and recruitment methods have been described previously [40-42]. Briefly, the TMM CommCohort Study began in May 2013 and recruited 80,000 residents of the Miyagi and Iwate Prefecture in Japan. Participants responded to questionnaire items regarding sociodemographic factors, lifestyle habits, and medical history; provided biospecimens, such as blood and urine; and underwent physiological measurements, such as height, weight, and eye examinations [41-43]. The TMM BirThree Cohort Study commenced in July 2013 and recruited 70,000 residents (approximately 40,000 adults) of the Miyagi Prefecture. The survey items were nearly identical to those used in the TMM CommCohort Study [40-42]. The 2 cohort studies conducted follow-up surveys, including mailed questionnaires and repeated health examinations at community support centers in Miyagi Prefecture and satellites in Iwate Prefecture. Individual clinical and genomic data were incorporated into the TMM database (dbTMM) [42].

### DryEyeRhythm Smartphone App

DryEyeRhythm, a free smartphone app for DED surveys and research, was launched in Japan in November 2016 and in the United States in April 2018 [15]. DryEyeRhythm collected electronic informed consent from all users. As illustrated in Figure 1A, participants provide demographic information, medical and lifestyle histories, and disease-specific questionnaire results for DED (Figure 1B, the Japanese version of the Ocular Surface Disease Index [J-OSDI]) [19,44], results of a depression rating scale results (Zung Self-rating Depression Scale [SDS]) [45], and work productivity details (Table S1 in Multimedia Appendix 1). Furthermore, DryEyeRhythm is equipped with functionality to measure the blink rate and maximum blink interval (MBI) of participants using smartphone cameras (Figure 1C) [7,20,46]. Collected data are automatically stored on the dedicated data server of the DryEyeRhythm smartphone app.

**Figure 1.** Screenshots of the DryEyeRhythm app. (A) Screenshot of the DryEyeRhythm test results. (B) screenshot of the DryEyeRhythm app-based J-OSDI. (C) Screenshot of the DryEyeRhythm exam menu. J-OSDI: Japanese version of the Ocular Surface Disease Index.




## Study Design and Participants

This study was designed as a prospective observational add-on cohort study (Figure 2). Eligible participants were aged  $\geq 20$  years at the time of providing informed consent, participated in the TMM CommCohort Study or TMM BirThree Cohort Study, and conducted a follow-up survey at the Community Support

Center of Sendai. A key inclusion criterion was that participants could use their smartphones. Participants were excluded if they did not have or use a smartphone or if their advice did not meet the operating system requirements (iOS 13.0 or later for iPhones; Android 8.0 or later for Android phones). Participants could withdraw their consent at any time before completing the second survey.

**Figure 2.** Schematic overview of the study design and participants.



We aim to recruit participants at the Community Support Center of Sendai in Miyagi Prefecture, Japan, by distributing brochures when they present for health surveys. Those interested in the study have been and will be recruited. Study recruitment will occur between March 2021 and March 2026. Participants enrolled between March 2021 and June 2022 were included in

the discovery stage cohort, whereas those enrolled between August 2024 and March 2026 will be included in the replication stage cohort. Participants will download and activate the DryEyeRhythm app [15] when they are recruited, and the cohort ID assigned to each participant will be scanned using a smartphone camera to connect the cohort ID to the app. The




participants will be required to review the study description and provide electronic informed consent by DryEyeRhythm. The DryEyeRhythm survey can be completed anywhere; however, participants who complete the survey at the Community Support Center of Sendai can receive assistance from genome medical research coordinators if they have questions regarding the survey.

## Study Procedures

Figure 3 shows a flowchart of the study. Participants visiting the Community Support Center of Sendai for health surveys and providing consent will complete questionnaires on sociodemographic factors, lifestyle habits, and medical history. They will also undergo blood and urine collection, physiological

measurements, and eye examinations. Subsequently, participants will install the DryEyeRhythm app on their smartphones. They will then provide data through DryEyeRhythm (Figure 1A) regarding their demographic characteristics, medical and lifestyle histories, DED symptoms based on the J-OSDI (Figure 1B), depression symptoms based on the SDS, work productivity, and app-based blink rate and MBI (Figure 1C) measurements through the smartphone camera. After 30 days, participants who receive a notification requesting a second round of data submission will provide another round of information on DED symptoms based on the same criteria as the first round using DryEyeRhythm. Participants who do not submit the second-round data will receive a reminder through a phone call.

**Figure 3.** Flowchart of this study. J-OSDI: Japanese version of the Ocular Surface Disease Index; SDS: Zung Self-rating Depression Scale.



## DED Diagnosis

Subjective symptoms of DED will be assessed using the 12-item J-OSDI questionnaire with 3 subscales: ocular symptoms, visual functioning, and environmental triggers [47]. Each response will be recorded on a 5-point scale (0="None of the time" to 4="All of the time" [4]), with "N/A" for questions not applicable to the user. The J-OSDI total score will be reported on a 100-point scale to determine the severity of DED symptoms (0-12, normal; 13-22, mild; 23-33, moderate; and 33-100, severe). The app-based J-OSDI has been validated in Japanese [44]. In this study, subjective symptoms of DED will be evaluated using the DryEyeRhythm-based (app-based) J-OSDI

(Figure 1B). The app-based J-OSDI has been validated and compared with the paper-based J-OSDI in a previous study [19].

The MBI is defined as the duration the participants could keep their eyes open [46]. MBI is positively correlated with tear film breakup time (TFBUT) [48]. In this study, the app-based MBI measured using DryEyeRhythm (Figure 1C) will be used for diagnosing DED. A previous study has demonstrated that the app-based MBI is a valid and reliable substitute measurement compared with the slit-lamp-based MBI [20].

We defined app-based DED as an app-based J-OSDI total score of  $\geq 13$  points and app-based MBI of  $\leq 12.4$  seconds [48]. The app-based diagnostic method has been validated as a simple

and noninvasive screening test for DED in previous studies [17,48]. The sensitivity, specificity, and area under the curve values for the app-based diagnostic method were 50%, 95%, and 0.91, respectively.

### GWAS for the Primary Outcome

Genotyping of participants and data imputations will be completed using TMM, as previously described [49]. Individuals will be excluded from the analysis if they have a low call rate ( $<0.95$ ), deviate from the mean of the major population by more than 4 SDs in genotyping principal component (PC) 1 and PC2, a medical history of Parkinson disease, or lack phenotypic and covariate data such as age, sex, and PCs. Variants will be excluded if they have a low call rate ( $<0.99$ ), low Hardy-Weinberg equilibrium exact test  $P$  value ( $P < 1 \times 10^{-6}$ ), low minor allele frequency ( $<0.01$ ), or low imputation quality ( $R^2 < 0.3$ ). The target outcome will be app-based DED. A stringent threshold of  $P < 5 \times 10^{-8}$  will denote genome-wide significance, minimizing false positives associated with multiple testing, and a suggestive threshold of  $P < 1 \times 10^{-5}$  to indicate potential associations that warrant further investigation. Only variants reaching the threshold ( $P < 5 \times 10^{-5}$ ) during the discovery stage will be selected for the replication stage. Logistic regression will be applied to binary outcomes, adjusting for confounding factors (such as age, sex, and PCs) using well-validated GWAS tools, including Plink2 [50].

### Secondary Outcome

The secondary outcomes of this study will include the association between app-based DED and patients'


sociodemographic factors, lifestyle habits, medical history, biospecimens such as blood and urine, and physiological measurements such as height, weight, and eye examination results [41-43]. These associations will be evaluated using logistic regression analysis and adjusted for confounding factors. A significance level of  $P < .05$  will be used.

### Sample Size Calculation

This study's sample size was calculated using the web-based tool Genetic Association Study Power Calculator [51]. The rs1143634 polymorphism in IL1B was selected as a candidate single-nucleotide polymorphism based on previous associations with non-Sjögren DED, with an odds ratio of 3.337 [26]. The minor allele frequency for rs1143634 was 0.047, based on data from the Japanese Multi Omics Reference Panel [52]. The prevalence of DED in the target population was estimated to be 30% [53], with a significance level of  $P < 5 \times 10^{-8}$ . The sample size was calculated to achieve an 80% statistical power, assuming 2000 participants (600 cases and 1400 controls, with a 30:70 case-control ratio).

As shown in Figure 4, the statistical power increased as the relative risk approached  $\geq 1.9$ . The odds ratio can be used as an approximation of the relative risk. With an odds ratio of 3.337 for rs1143634, the sample size was deemed adequate for detecting associations based on the effect size observed in a previous study [26]. The sample size was increased by 10% to account for potential exclusions, resulting in a final recruitment target of 2200 participants. Of these, 1200 participants were included in the discovery stage, and 1000 participants will be included in the replication stage.

**Figure 4.** Statistical power analysis.



### Statistical Analyses

The initial data selection for the DryEyeRhythm dataset collected will be conducted for each cohort ID. If the dataset contains complete data (data without missing values), the first available dataset will be used as the initial dataset. If only incomplete data are registered, the first incomplete dataset will be used as the initial dataset. If complete data are registered on

or after 30 days and before 37 days from the initial dataset, the first dataset among them will be used as the second dataset. If only incomplete data are registered within this period, the first dataset among them will be used as the second dataset. The demographic characteristics of the participants will be analyzed as the input values of the initial data. The month of a participant's inclusion will be defined as the month when their initial data are recorded. The ophthalmic data analyzed in this

study will be measured at the time of recruitment for the TMM CommCohort Study and TMM BirThree Cohort Study and stored in the dbTMM [40–42].

Continuous variables will be presented as median (IQR) values and categorical variables as percentages. The Mann-Whitney *U* test will be used for continuous variables, and the chi-square test for categorical variables. All analyses will be conducted with a significance level of .05 using a 2-sided test. The associations between app-based DED and factors stored in the dbTMM and measured through DryEyeRhythm will be evaluated using the logistic regression analysis. This model will incorporate participants' characteristics (such as age, gender, height, weight, and medical history), lifestyle factors, environmental factors (including residential environment), and ophthalmic examination results as variables to calculate fully adjusted odds ratios, accounting for various confounding factors. All data will be analyzed using Stata (version 18.0; StataCorp) and R (version 4.2.1; R Foundation for Statistical Computing).

### Ethical Considerations

This study was approved by the Ethics Committee of the Tohoku University TMM Organization (approval number: 2023-4-188; September 10, 2023, version 1), the Independent Ethics Committee of Juntendo University Faculty of Medicine, and the Ethics Committee of Iwate Medical University, adhering to the principles outlined in the tenets of the Declaration of Helsinki. The research protocol was reviewed by the Ethics Committee of the Tohoku University TMM Organization on behalf of multiple institutions. All participants will provide informed consent upon visiting the Community Support Center, Sendai, Miyagi, Japan. In addition, electronic informed consent will be obtained upon the first activation of the DryEyeRhythm smartphone app. The consent process includes approval for the use of data from the Tohoku Medical Megabank database. To ensure participants' confidentiality, all data will be anonymized, with participants identified using a cohort ID that prevents personal identification. Participants will receive an honorarium of 500 Yen (US \$3.50) per survey (up to a maximum of 1000 Yen [US \$7]) for completing the DryEyeRhythm surveys.

### Results

Participant enrollment for the discovery stage was performed from August 1, 2021, to June 30, 2022. Enrollment for the replication stage will be performed from August 31, 2024, to March 31, 2026. Data analysis will be completed by September 2026, and results will be reported by March 2027.

### Discussion

Implementing the principles of P4 medicine through cross-hierarchical analyses, which include comprehensive and personalized digital health and genomic datasets, may be crucial for preventing the onset or progression of highly multifactorial DED. By integrating DryEyeRhythm, our mHealth app for DED research, with the TMM project, we establish a comprehensive database for DED that integrates genomic data from the biobank with multifaceted datasets (ie, lifestyle, biosensor records, and demographics) collected through our app. Using this robust

dataset, we identify new gene loci and polymorphisms associated with DED pathogenesis and progression, as well as new DED subtypes and their characteristics through stratification strategies. This approach can also be extended to other fields of medicine, providing insights into the underlying pathophysiology of various multifactorial diseases.

We conducted a systematic review using PubMed and Embase for all research articles published until April 15, 2024, using the search terms “(dry eye) AND ((genome) OR (polymorphism) OR (SNP) OR (variant) OR (locus) OR (loci) (mutation)).” This systematic review did not identify any existing publications that collected real-world, daily DED-related health data, such as lifestyle patterns, environmental status, biosensor inputs, or subjective symptoms using mHealth technology. However, we identified 20 reports on gene mutations or polymorphisms associated with DED onset and severity [22–39,54,55]. No studies have conducted GWAS to identify loci associated with DED. Therefore, the proposed approach marks the first attempt to create a holistic database for DED using genomic and digital health data. This integration may reveal unknown aspects of DED regarding its variability, heterogeneity, and implementation of P4 medicine. In addition, we highlight the new use and value of biobanks in global health care research communities through this initiative, eventually promoting the incorporation of genomic studies into standard clinical practice.

The add-on portion of this study will be conducted through DryEyeRhythm to provide DED diagnostic support [15]. The diagnostic criteria for DED in Japan include positive subjective symptoms on the DED-specific symptom questionnaire and decreased TFBUT [44,56]. To meet these criteria, DryEyeRhythm first administers the J-OSDI questionnaire through its app interface [17,46,48]. Instead of directly measuring TFBUT, the app measures the MBI of the participants, which is positively correlated with TFBUT [17,46,48]. Our previous studies on the comeasurement of the app-based J-OSDI total score and MBI demonstrated sufficient validity, reliability, and equivalence to the traditional diagnostic standard [19,20]. Regarding diagnostic performance, the positive and negative predictive values were reported to be 91.3% and 69.1%, respectively [17]. Furthermore, using data collected through DryEyeRhythm, we developed and tested an original stratification algorithm that identified 7 DED subtypes based on subjective symptoms [7]. In this study, we applied the above stratification technique to better detect DED subtypes and understand DED pathophysiology by identifying the digital phenotypic characteristics of each cluster.

Another crucial aspect of this protocol is the cross-hierarchical analysis using real-time, day-to-day digital data and lifestyle factors, which are difficult to capture in traditional cohort studies involving established biobanks [6,7,9,15]. Typically, biobanks require participants to visit facilities or send samples directly for collection. Conversely, mHealth offers the advantage of nonintrusive, longitudinal data collection, closely reflecting real-world data as facility-attained data are readily affected by undesired variables (such as white-coat syndrome and masked hypertension) [57]. Such data characteristics that closely resemble real-world data can be particularly crucial for perfecting the future implementation of P4 medicine [57]. For

DED, day-to-day health data can be important as they are associated with daily activities and factors immeasurable in a facility setting, such as on-screen time and living environment. With the use of common smart devices and attached sensors, clinicians and researchers can access the data above. Objective data points, including DED questionnaire scores and biosensor data, can reduce barriers to access and cost, as mHealth apps can be operated by users without requiring specialized examination tools or personnel [17,19,20,58]. Physical and biological specimens such as genomic samples, secretions, or hair will still be crucial but with a shift toward using mailed specimens, allowing for a study cohort without geographic limitations to populations near specific research centers. Cohort studies in Western countries where participants provided consent through a smartphone app and physical specimens through the mail have been reported [59,60]. Although no similar attempts have been made in ophthalmology, DryEyeRhythm could serve as a platform to recruit cohorts similarly and expand the use of existing and prospective biobanks.

Our protocol has some limitations, consistent with those identified in previous studies using smartphone apps [9,15]. First, this study may be prone to recall bias due to the reliance on self-administered questionnaires, which may lead to an overestimation of DED prevalence in the community. On the other hand, in evaluating subjective symptoms of DED, self-reported questionnaires, such as the J-OSDI questionnaire, are commonly used in standard clinical DED diagnostic methods [56]. Therefore, the impact of using a self-reported questionnaire for subjective DED symptoms on the study results is likely

minimal. Second, selection bias may occur, as individuals concerned about DED prevalence and those with previous symptoms may be more likely to participate due to the voluntary registration process. In addition, older adults or those lacking access to smart devices will have difficulty participating in this study. This study will target participants of the TMM CommCohort Study and the TMM BirThree Cohort Study, which geographically restricts the pool of participants. The limitations in the geographical and demographic representativeness of the sample may introduce bias and affect the generalizability of the study results. Third, this study will diagnose DED using app-based J-OSDI and MBI metrics without conducting clinical examinations, such as TFBUT, the Schirmer test, osmolality measurements, and ocular surface staining [9,11,46]. The difference in this method may affect the study results. However, this app-based DED diagnostic method has been validated for reliability and validity against the standard DED diagnostic method, which uses the paper-based J-OSDI questionnaire and TFBUT [17,56]. The positive predictive and negative predictive values of the app-based DED assessment were 91.3% and 69.1%, respectively, with an area under the curve of 0.91. Therefore, the effect of differences in the method of diagnosis of DED on the results of this study is likely minimal.

In conclusion, by establishing a comprehensive database for DED that integrates existing medical biobank data with highly personalized and holistic mHealth data, this study may discover a new biobank value and contribute to the implementation of genomics in clinical practice.

## Acknowledgments

The authors thank Medical Logue and InnoJin for developing the DryEyeRhythm smartphone app and genome medical research coordinators and administrative assistants at the Community Support Center of Sendai. This research was supported in part by the Tohoku Medical Megabank Project (Tohoku University) from MEXT (Tohoku Medical Megabank Organization), the Japan Agency for Medical Research and Development (AMED; grant number JP21tm0124005 [Tohoku Medical Megabank Organization]), BioBank-Construction and Utilization Biobank for Genomic Medicine Realization: B-Cure from AMED (grant number JP21tm0424601), Japan Society for the Promotion of Science KAKENHI grants (20KK0207 [TI], 20K23168 [AMI], 21K17311 [AMI], 21K20998 [AE], 22K16983 [AE], 23K16364 [AMI], 23K18406 [TI], and 24K19796 [AE]), Japan Science and Technology Agency FOREST program (24012732 [TI]), Kondou Kinen Medical Foundation, Medical Research Encouragement Prize 2020 [TI], Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen Pharmaceutical's Founder 2020 [TI], Nishikawa Medical Foundation, Medical Research Encouragement Prize 2020 [TI], the OTC Self-Medication Promotion Foundation [TI and YO], Takeda Science Foundation 2022 [TI], and Research Grants in the Natural Sciences 2024, The Mitsubishi Foundation. The sponsors had no role in the design or performance of the study, data collection and management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, or in the decision to submit the manuscript for publication.

## Data Availability

All data are available in the main text. The code supporting the findings of this study will be made available from the corresponding author upon reasonable request. Data processing and analysis will be performed using STATA version 18.0.

## Authors' Contributions

KN, YA, and TI had complete access to all data in this study and took responsibility for the integrity of the data and the accuracy of the data analysis. KN, YA, and TI managed the study concept and design. KN, YA, NF, SO, AS, AU, YS, YOY, FN, JS, TN, SN, MT, TK, RS, AH, SK, AE, AMI, MN, AM, SN, and TI handled acquisition, analysis, or interpretation of data. KN, JS, AY, and TI managed the drafting of the manuscript. KN, JS, AM, SN, and TI conducted critical revision of the manuscript for important intellectual content. AMI, AE, and TI obtained funding. KN, YA, AMI, and TI conducted statistical analysis. NF, SO, AS, AU,



AM, SN, and TI handled administrative, technical, or material support. NF, SO, AS, AM, SN, and TI contributed to supervision. All authors read and approved of the final manuscript.

## Conflicts of Interest

The DryEyeRhythm smartphone app was developed by Juntendo University (Tokyo, Japan) and InnoJin (Tokyo, Japan). TI is the owner of InnoJin. KN and AMI reported receiving personal fees from InnoJin. SN reports grants from Kowa, Mitsubishi Tanabe Pharma Corp, Alcon Japan, Santen Pharmaceutical, Machida Endoscope, Wakamoto Pharmaceutical, Bayer Yakuhin, Senju Pharmaceutical, Nippon Boehringer Ingelheim, Chugai Pharmaceutical, Hoya Corp, and Novartis Pharma KK, outside the submitted work. TI reports nonfinancial support from Lion Corporation and Sony Network Communication; grants from Johnson & Johnson Vision Care, Yuimedi, ROHTO Pharmaceutical, Kobayashi Pharmaceutical, and Kandenko; and personal fees from Santen Pharmaceutical and InnoJin, outside the submitted work.

## Multimedia Appendix 1

DryEyeRhythm questions.

[PDF File (Adobe PDF File), 1121 KB-Multimedia Appendix 1]

## References

1. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. *Ocul Surf*. 2017;15(3):334-365. [doi: [10.1016/j.jtos.2017.05.003](https://doi.org/10.1016/j.jtos.2017.05.003)] [Medline: [28736337](#)]
2. Ding J, Sullivan DA. Aging and dry eye disease. *Exp Gerontol*. 2012;47(7):483-490. [FREE Full text] [doi: [10.1016/j.exger.2012.03.020](https://doi.org/10.1016/j.exger.2012.03.020)] [Medline: [22569356](#)]
3. Courtin R, Pereira B, Naughton G, Chamoux A, Chiambaretta F, Lanhers C, et al. Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis. *BMJ Open*. 2016;6(1):e009675. [FREE Full text] [doi: [10.1136/bmjopen-2015-009675](https://doi.org/10.1136/bmjopen-2015-009675)] [Medline: [26769784](#)]
4. Giannaccare G, Vaccaro S, Mancini A, Scorgia V. Dry eye in the COVID-19 era: how the measures for controlling pandemic might harm ocular surface. *Graefes Arch Clin Exp Ophthalmol*. 2020;258(11):2567-2568. [FREE Full text] [doi: [10.1007/s00417-020-04808-3](https://doi.org/10.1007/s00417-020-04808-3)] [Medline: [32561978](#)]
5. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. *Cornea*. 2011;30(4):379-387. [doi: [10.1097/ICO.0b013e3181f7f363](https://doi.org/10.1097/ICO.0b013e3181f7f363)] [Medline: [21045640](#)]
6. Inomata T, Sung J, Nakamura M, Iwagami M, Okumura Y, Fujio K, et al. Cross-hierarchical integrative research network for heterogenous eye disease toward P4 medicine: A narrative review. *Juntendo Medical Journal*. 2021;67(6):519-529. [doi: [10.14789/jmj.jmj21-0023-r](https://doi.org/10.14789/jmj.jmj21-0023-r)]
7. Inomata T, Nakamura M, Sung J, Midorikawa-Inomata A, Iwagami M, Fujio K, et al. Smartphone-based digital phenotyping for dry eye toward P4 medicine: a crowdsourced cross-sectional study. *NPJ Digit Med*. 2021;4(1):171. [FREE Full text] [doi: [10.1038/s41746-021-00540-2](https://doi.org/10.1038/s41746-021-00540-2)] [Medline: [34931013](#)]
8. Inomata T, Sung J, Nakamura M, Iwagami M, Okumura Y, Iwata N, et al. Using medical big data to develop personalized medicine for dry eye disease. *Cornea*. 2020;39 Suppl 1:S39-S46. [doi: [10.1097/ICO.0000000000002500](https://doi.org/10.1097/ICO.0000000000002500)] [Medline: [33055549](#)]
9. Inomata T, Iwagami M, Nakamura M, Shiang T, Yoshimura Y, Fujimoto K, et al. Characteristics and risk factors associated with diagnosed and undiagnosed symptomatic dry eye using a smartphone application. *JAMA Ophthalmol*. 2020;138(1):58-68. [FREE Full text] [doi: [10.1001/jamaophthalmol.2019.4815](https://doi.org/10.1001/jamaophthalmol.2019.4815)] [Medline: [31774457](#)]
10. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. *Ocul Surf*. 2017;15(3):575-628. [doi: [10.1016/j.jtos.2017.05.006](https://doi.org/10.1016/j.jtos.2017.05.006)] [Medline: [28736343](#)]
11. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C, et al. TFOS DEWS II definition and classification report. *Ocul Surf*. 2017;15(3):276-283. [doi: [10.1016/j.jtos.2017.05.008](https://doi.org/10.1016/j.jtos.2017.05.008)] [Medline: [28736335](#)]
12. Vehof J, Wang B, Kozareva D, Hysi PG, Snieder H, Hammond CJ. The heritability of dry eye disease in a female twin cohort. *Invest Ophthalmol Vis Sci*. 2014;55(11):7278-7283. [FREE Full text] [doi: [10.1167/iovs.14-15200](https://doi.org/10.1167/iovs.14-15200)] [Medline: [25249607](#)]
13. mHealth: New Horizons for Health Through Mobile Technologies: Second Global Survey on eHealth. World Health Organization. URL: <https://apps.who.int/iris/handle/10665/44607> [accessed 2025-04-12]
14. Aruljyothi L, Janakiraman A, Malligarjun B, Babu BM. Smartphone applications in ophthalmology: A quantitative analysis. *Indian J Ophthalmol*. 2021;69(3):548-553. [FREE Full text] [doi: [10.4103/ijo.IJO\\_1480\\_20](https://doi.org/10.4103/ijo.IJO_1480_20)] [Medline: [33595469](#)]
15. Inomata T, Nakamura M, Iwagami M, Shiang T, Yoshimura Y, Fujimoto K, et al. Risk factors for severe dry eye disease: crowdsourced research using dryEyeRhythm. *Ophthalmology*. 2019;126(5):766-768. [doi: [10.1016/j.ophtha.2018.12.013](https://doi.org/10.1016/j.ophtha.2018.12.013)] [Medline: [30550734](#)]
16. Gambhir SS, Ge TJ, Vermesh O, Spitler R. Toward achieving precision health. *Sci Transl Med*. 2018;10(430). [FREE Full text] [doi: [10.1126/scitranslmed.aao3612](https://doi.org/10.1126/scitranslmed.aao3612)] [Medline: [29491186](#)]

17. Okumura Y, Inomata T, Midorikawa-Inomata A, Sung J, Fujio K, Akasaki Y, et al. DryEyeRhythm: A reliable and valid smartphone application for the diagnosis assistance of dry eye. *Ocul Surf*. 2022;25:19-25. [doi: [10.1016/j.jtos.2022.04.005](https://doi.org/10.1016/j.jtos.2022.04.005)] [Medline: [35483601](https://pubmed.ncbi.nlm.nih.gov/35483601/)]
18. Nagino K, Okumura Y, Yamaguchi M, Sung J, Nagao M, Fujio K, et al. Diagnostic ability of a smartphone app for dry eye disease: protocol for a multicenter, open-label, prospective, and cross-sectional study. *JMIR Res Protoc*. 2023;12:e45218. [FREE Full text] [doi: [10.2196/45218](https://doi.org/10.2196/45218)] [Medline: [36912872](https://pubmed.ncbi.nlm.nih.gov/36912872/)]
19. Nagino K, Okumura Y, Akasaki Y, Fujio K, Huang T, Sung J, et al. Smartphone app-based and paper-based patient-reported outcomes using a disease-specific questionnaire for dry eye disease: randomized crossover equivalence study. *J Med Internet Res*. 2023;25:e42638. [FREE Full text] [doi: [10.2196/42638](https://doi.org/10.2196/42638)] [Medline: [37535409](https://pubmed.ncbi.nlm.nih.gov/37535409/)]
20. Fujio K, Nagino K, Huang T, Sung J, Akasaki Y, Okumura Y, et al. Clinical utility of maximum blink interval measured by smartphone application dryEyeRhythm to support dry eye disease diagnosis. *Sci Rep*. 2023;13(1):13583. [FREE Full text] [doi: [10.1038/s41598-023-40968-y](https://doi.org/10.1038/s41598-023-40968-y)] [Medline: [37604900](https://pubmed.ncbi.nlm.nih.gov/37604900/)]
21. Vehof J, Zavos HMS, Lachance G, Hammond CJ, Williams FMK. Shared genetic factors underlie chronic pain syndromes. *Pain*. 2014;155(8):1562-1568. [doi: [10.1016/j.pain.2014.05.002](https://doi.org/10.1016/j.pain.2014.05.002)] [Medline: [24879916](https://pubmed.ncbi.nlm.nih.gov/24879916/)]
22. Imbert Y, Foulks GN, Brennan MD, Jumblatt MM, John G, Shah HA, et al. MUC1 and estrogen receptor alpha gene polymorphisms in dry eye patients. *Exp Eye Res*. 2009;88(3):334-338. [doi: [10.1016/j.exer.2008.05.019](https://doi.org/10.1016/j.exer.2008.05.019)] [Medline: [18619437](https://pubmed.ncbi.nlm.nih.gov/18619437/)]
23. Meng YF, Xin Q, Lu J, Xiao P, Li J. Association between single nucleotide polymorphisms in the vitamin D receptor and incidence of dry eye disease in Chinese han population. *Med Sci Monit*. 2019;25:4759-4765. [FREE Full text] [doi: [10.12659/MSM.915434](https://doi.org/10.12659/MSM.915434)] [Medline: [31243261](https://pubmed.ncbi.nlm.nih.gov/31243261/)]
24. Hallak JA, Tibrewal S, Mohindra N, Gao X, Jain S. Single nucleotide polymorphisms in the BDNF, VDR, and DNASE 1 genes in dry eye disease patients: A case-control study. *Invest Ophthalmol Vis Sci*. 2015;56(10):5990-5996. [FREE Full text] [doi: [10.1167/iovs.15-17036](https://doi.org/10.1167/iovs.15-17036)] [Medline: [26393465](https://pubmed.ncbi.nlm.nih.gov/26393465/)]
25. Safonova TN, Zaitseva GV, Burdennyy AM, Loginov VI. [Association of polymorphic markers rs7947461 of the TRIM21 gene and rs33996649 of the PTPN22 gene with the risk of developing exogenous dry eye syndrome]. *Vestn Oftalmol*. 2021;137(5. Vyp. 2):217-223. [doi: [10.17116/oftalma2021137052217](https://doi.org/10.17116/oftalma2021137052217)] [Medline: [34669330](https://pubmed.ncbi.nlm.nih.gov/34669330/)]
26. Na KS, Mok JW, Kim JY, Joo CK. Proinflammatory gene polymorphisms are potentially associated with Korean non-Sjogren dry eye patients. *Mol Vis*. 2011;17:2818-2823. [FREE Full text] [Medline: [22128229](https://pubmed.ncbi.nlm.nih.gov/22128229/)]
27. Ren G, Shao T, Zhuang Y, Hu H, Zhang X, Huang J, et al. Association of killer cell immunoglobulin-like receptor and human leukocyte antigen-C genotype with dry eye disease in a Chinese Han population. *Genet Test Mol Biomarkers*. 2012;16(8):910-914. [doi: [10.1089/gtmb.2011.0355](https://doi.org/10.1089/gtmb.2011.0355)] [Medline: [22509813](https://pubmed.ncbi.nlm.nih.gov/22509813/)]
28. He Y, Li X, Bao Y, Sun J, Liu J. [The correlation of polymorphism of estrogen receptor gene to dry eye syndrome in postmenopausal women]. *Yan Ke Xue Bao*. 2006;22(4):233-236. [Medline: [17378156](https://pubmed.ncbi.nlm.nih.gov/17378156/)]
29. Ben-Eli H, Gomel N, Aframian DJ, Abu-Seir R, Perlman R, Ben-Chetrit E, et al. SNP variations in IL10, TNF $\alpha$  and TNFAIP3 genes in patients with dry eye syndrome and sjogren's syndrome. *J Inflamm (Lond)*. 2019;16:6. [FREE Full text] [doi: [10.1186/s12950-019-0209-z](https://doi.org/10.1186/s12950-019-0209-z)] [Medline: [30923465](https://pubmed.ncbi.nlm.nih.gov/30923465/)]
30. Montúfar-Robles I, Lara-García S, Barbosa-Cobos RE, Vargas-Alarcón G, Hernández-Molina G, Fragoso JM, et al. BLK and BANK1 variants and interactions are associated with susceptibility for primary Sjögren's syndrome and with some clinical features. *Cell Immunol*. 2021;363:104320. [doi: [10.1016/j.cellimm.2021.104320](https://doi.org/10.1016/j.cellimm.2021.104320)] [Medline: [33756160](https://pubmed.ncbi.nlm.nih.gov/33756160/)]
31. Inanir A, Yigit S, Tekcan A, Pinarli FA, Inanir S, Karakus N. Angiotensin converting enzyme and methylenetetrahydrofolate reductase gene variations in fibromyalgia syndrome. *Gene*. 2015;564(2):188-192. [doi: [10.1016/j.gene.2015.03.051](https://doi.org/10.1016/j.gene.2015.03.051)] [Medline: [25824380](https://pubmed.ncbi.nlm.nih.gov/25824380/)]
32. Safonova TN, Surnina ZV, Zaitseva GV, Burdenniy AM, Loginov VI. The role of polymorphic markers rs1478604, rs2292305, and rs2228262 in THBS1 gene in the development of autoimmune dry eye syndrome. *Bull Exp Biol Med*. 2020;169(5):707-709. [doi: [10.1007/s10517-020-04960-0](https://doi.org/10.1007/s10517-020-04960-0)] [Medline: [32990854](https://pubmed.ncbi.nlm.nih.gov/32990854/)]
33. Polanská V, Serý O, Fojtík Z, Hlinomazová Z. [The presence of dry eye syndrome and corneal complications in patients with rheumatoid arthritis and its association with -174 gene polymorphism for interleukin 6]. *Cesk Slov Oftalmol*. 2008;64(2):77-80. [Medline: [18419107](https://pubmed.ncbi.nlm.nih.gov/18419107/)]
34. de Souza TR, de Albuquerque Tavares Carvalho A, Duarte ÂP, Porter SR, Leão JC, Gueiros LA. Th1 and Th2 polymorphisms in sjögren's syndrome and rheumatoid arthritis. *J Oral Pathol Med*. 2014;43(6):418-426. [doi: [10.1111/jop.12149](https://doi.org/10.1111/jop.12149)] [Medline: [24393164](https://pubmed.ncbi.nlm.nih.gov/24393164/)]
35. Safonova TN, Zaitseva GV, Loginov VI, Burdenniy AM, Lukina SS. [Association of polymorphisms of the TRIM21 gene with the severity of dry keratoconjunctivitis in rheumatoid arthritis and Sjogren's disease]. *Vestn Oftalmol*. 2019;135(5. Vyp. 2):192-198. [doi: [10.17116/oftalma2019135052192](https://doi.org/10.17116/oftalma2019135052192)] [Medline: [31691659](https://pubmed.ncbi.nlm.nih.gov/31691659/)]
36. Appel S, Le Hellard S, Bruland O, Brun JG, Omdal R, Kristjansdottir G, et al. Potential association of muscarinic receptor 3 gene variants with primary Sjogren's syndrome. *Ann Rheum Dis*. 2011;70(7):1327-1329. [doi: [10.1136/ard.2010.138966](https://doi.org/10.1136/ard.2010.138966)] [Medline: [21450750](https://pubmed.ncbi.nlm.nih.gov/21450750/)]

37. Rodríguez-Rodríguez L, Ramón Lamas J, Abásolo L, Baena S, Olano-Martin E, Collado A, et al. The rs3771863 single nucleotide polymorphism of the TACR1 gene is associated to a lower risk of sicca syndrome in fibromyalgia patients. *Clin Exp Rheumatol*. 2015;33(1 Suppl 88):S33-S40. [Medline: [25786041](#)]
38. Soto-Cárdenas MJ, Gandía M, Brito-Zerón P, Arias MT, Armiger N, Bové A, et al. Etiopathogenic role of surfactant protein d in the clinical and immunological expression of primary sjögren syndrome. *J Rheumatol*. 2015;42(1):111-118. [doi: [10.3899/jrheum.140394](#)] [Medline: [25362659](#)]
39. Acuna K, Choudhary A, Locatelli E, Rodríguez DA, Martin ER, Levitt RC, et al. Impact of tumor necrosis factor receptor 1 ( ) polymorphism on dry eye disease. *Biomolecules*. 2023;13(2):262. [FREE Full text] [doi: [10.3390/biom13020262](#)] [Medline: [36830631](#)]
40. Kuriyama S, Yaegashi N, Nagami F, Arai T, Kawaguchi Y, Osumi N, et al. The tohoku medical megabank project: design and mission. *J Epidemiol*. 2016;26(9):493-511. [FREE Full text] [doi: [10.2188/jea.JE20150268](#)] [Medline: [27374138](#)]
41. Hozawa A, Tanno K, Nakaya N, Nakamura T, Tsuchiya N, Hirata T, et al. Study profile of the Tohoku medical megabank community-based cohort study. *J Epidemiol*. 2021;31(1):65-76. [FREE Full text] [doi: [10.2188/jea.JE20190271](#)] [Medline: [31932529](#)]
42. Ogishima S, Nagaie S, Mizuno S, Ishiwata R, Iida K, Shimokawa K, Tohoku Medical Megabank Project Study Group, et al. dbTMM: an integrated database of large-scale cohort, genome and clinical data for the Tohoku medical megabank project. *Hum Genome Var*. 2021;8(1):44. [FREE Full text] [doi: [10.1038/s41439-021-00175-5](#)] [Medline: [34887386](#)]
43. Fuse N, Sakurai M, Motoike IN, Kojima K, Takai-Igarashi T, Nakaya N, et al. Genome-wide association study of axial length in population-based cohorts in Japan: the Tohoku medical megabank organization eye study. *Ophthalmol Sci*. 2022;2(1):100113. [FREE Full text] [doi: [10.1016/j.xops.2022.100113](#)] [Medline: [36246171](#)]
44. Midorikawa-Inomata A, Inomata T, Nojiri S, Nakamura M, Iwagami M, Fujimoto K, et al. Reliability and validity of the Japanese version of the ocular surface disease index for dry eye disease. *BMJ Open*. 2019;9(11):e033940. [FREE Full text] [doi: [10.1136/bmjopen-2019-033940](#)] [Medline: [31772113](#)]
45. Zung WW. A Self-rating depression scale. *Arch Gen Psychiatry*. 1965;12:63-70. [doi: [10.1001/archpsyc.1965.01720310065008](#)] [Medline: [14221692](#)]
46. Inomata T, Iwagami M, Hiratsuka Y, Fujimoto K, Okumura Y, Shiang T, et al. Maximum blink interval is associated with tear film breakup time: A new simple, screening test for dry eye disease. *Sci Rep*. 2018;8(1):13443. [FREE Full text] [doi: [10.1038/s41598-018-31814-7](#)] [Medline: [30194447](#)]
47. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. *Arch Ophthalmol*. 2000;118(5):615-621. [doi: [10.1001/archophth.118.5.615](#)] [Medline: [10815152](#)]
48. Hirosawa K, Inomata T, Sung J, Nakamura M, Okumura Y, Midorikawa-Inomata A, et al. Diagnostic ability of maximum blink interval together with Japanese version of ocular surface disease index score for dry eye disease. *Sci Rep*. 2020;10(1):18106. [FREE Full text] [doi: [10.1038/s41598-020-75193-4](#)] [Medline: [33093551](#)]
49. Yasuda J, Kinoshita K, Katsuoka F, Danjoh I, Sakurai-Yaeta M, Motoike IN, Tohoku Medical Megabank Project Study Group, et al. Genome analyses for the tohoku medical megabank project towards establishment of personalized healthcare. *J Biochem*. 2019;165(2):139-158. [doi: [10.1093/jb/mvy096](#)] [Medline: [30452759](#)]
50. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7. [FREE Full text] [doi: [10.1186/s13742-015-0047-8](#)] [Medline: [25722852](#)]
51. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat Genet*. 2006;38(2):209-213. [doi: [10.1038/ng1706](#)] [Medline: [16415888](#)]
52. Tadaka S, Kawashima J, Hishinuma E, Saito S, Okamura Y, Otsuki A, et al. jMorp: Japanese multi-omics reference panel update report 2023. *Nucleic Acids Res*. 2024;52(D1):D622-D632. [FREE Full text] [doi: [10.1093/nar/gkad978](#)] [Medline: [37930845](#)]
53. Hanyuda A, Sawada N, Uchino M, Kawashima M, Yuki K, Tsubota K, et al. JPHC-NEXT Study Group. Physical inactivity, prolonged sedentary behaviors, and use of visual display terminals as potential risk factors for dry eye disease: JPHC-NEXT study. *Ocul Surf*. 2020;18(1):56-63. [doi: [10.1016/j.jtos.2019.09.007](#)] [Medline: [31563549](#)]
54. Imbert Y, Darling DS, Jumblatt MM, Foulks GN, Couzin EG, Steele PS, et al. MUC1 splice variants in human ocular surface tissues: possible differences between dry eye patients and normal controls. *Exp Eye Res*. 2006;83(3):493-501. [doi: [10.1016/j.exer.2006.01.031](#)] [Medline: [16631167](#)]
55. Tsubota K, Fujishima H, Toda I, Katagiri S, Kawashima Y, Saito I. Increased levels of epstein-barr virus DNA in lacrimal glands of Sjögren's syndrome patients. *Acta Ophthalmol Scand*. 1995;73(5):425-430. [doi: [10.1111/j.1600-0420.1995.tb00302.x](#)] [Medline: [8751122](#)]
56. Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M, et al. Asia Dry Eye Society. New perspectives on dry eye definition and diagnosis: A consensus report by the Asia dry eye society. *Ocul Surf*. 2017;15(1):65-76. [FREE Full text] [doi: [10.1016/j.jtos.2016.09.003](#)] [Medline: [27725302](#)]
57. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 international society of hypertension global hypertension practice guidelines. *Hypertension*. 2020;75(6):1334-1357. [FREE Full text] [doi: [10.1161/HYPERTENSIONAHA.120.15026](#)] [Medline: [32370572](#)]

58. Inomata T, Nakamura M, Iwagami M, Sung J, Nakamura M, Ebihara N, et al. Symptom-based stratification for hay fever: A crowdsourced study using the smartphone application AllerSearch. *Allergy*. 2021;76(12):3820-3824. [doi: [10.1111/all.15078](https://doi.org/10.1111/all.15078)] [Medline: [34480802](https://pubmed.ncbi.nlm.nih.gov/34480802/)]
59. Guintivano J, Krohn H, Lewis C, Byrne EM, Henders AK, Ploner A, et al. PPD ACT: an app-based genetic study of postpartum depression. *Transl Psychiatry*. 2018;8(1):260. [FREE Full text] [doi: [10.1038/s41398-018-0305-5](https://doi.org/10.1038/s41398-018-0305-5)] [Medline: [30498212](https://pubmed.ncbi.nlm.nih.gov/30498212/)]
60. Collaton J, Dennis CL, Taylor VH, Grigoriadis S, Oberlander TF, Frey BN, et al. The PPD-ACT app in Canada: feasibility and a latent class analysis of participants with postpartum depression recruited to a psychiatric genetics study using a mobile application. *BMC Psychiatry*. 2022;22(1):735. [FREE Full text] [doi: [10.1186/s12888-022-04363-7](https://doi.org/10.1186/s12888-022-04363-7)] [Medline: [36434566](https://pubmed.ncbi.nlm.nih.gov/36434566/)]

## Abbreviations

**dbTMM:** database Tohoku Medical Megabank  
**DED:** dry eye disease  
**GWAS:** genome-wide association studies  
**J-OSDI:** Japanese version of the Ocular Surface Disease Index  
**MBI:** maximum blink interval  
**mHealth:** mobile health  
**PC:** principal component  
**P4 medicine:** predictive, preventive, personalized, and participatory medicine  
**SDS:** Zung Self-rating Depression Scale  
**TFBUT:** tear film breakup time  
**TMM:** Tohoku Medical Megabank  
**TMM BirThree Cohort:** TMM Birth and Three-Generation Cohort Study  
**TMM CommCohort:** TMM Community-Based Cohort Study

*Edited by A Schwartz; submitted 23.10.24; peer-reviewed by W Yang; comments to author 11.02.25; revised version received 22.02.25; accepted 02.04.25; published 12.05.25*

### *Please cite as:*

Nagino K, Akasaki Y, Fuse N, Ogishima S, Shimizu A, Uruno A, Sutoh Y, Otsuka-Yamasaki Y, Nagami F, Seita J, Nakamura T, Nagaie S, Taira M, Kobayashi T, Shimizu R, Hozawa A, Kuriyama S, Eguchi A, Midorikawa-Inomata A, Nakamura M, Murakami A, Nakao S, Inomata T

*Integration of Digital Phenotyping and Genomics for Dry Eye Disease: Protocol for a Prospective Cohort Study*

*JMIR Res Protoc* 2025;14:e67862

URL: <https://www.researchprotocols.org/2025/1/e67862>

doi: [10.2196/67862](https://doi.org/10.2196/67862)

PMID:

©Ken Nagino, Yasutsugu Akasaki, Nobuo Fuse, Soichi Ogishima, Atsushi Shimizu, Akira Uruno, Yoichi Sutoh, Yayoi Otsuka-Yamasaki, Fuji Nagami, Jun Seita, Tomohiro Nakamura, Satoshi Nagaie, Makiko Taira, Tomoko Kobayashi, Ritsuko Shimizu, Atsushi Hozawa, Shinichi Kuriyama, Atsuko Eguchi, Akie Midorikawa-Inomata, Masahiro Nakamura, Akira Murakami, Shintaro Nakao, Takenori Inomata. Originally published in JMIR Research Protocols (<https://www.researchprotocols.org/>), 12.05.2025. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <https://www.researchprotocols.org/>, as well as this copyright and license information must be included.